Verastem (VSTM) Long-Term Debt Repayments (2025)
Verastem's quarterly Long-Term Debt Repayments came in at -$1000.0 in Q4 2025, down 100.0% quarter-over-quarter from $42.6 million in Q1 2025.
Verastem has reported Long-Term Debt Repayments for 1 years, with the latest figure at -$1000.0 in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to -$1000.0; the trailing twelve-month figure through Dec 2025 stood at $42.6 million (changed N/A YoY), and the FY2025 full-year result was $42.6 million, changed N/A from the prior year.
- Long-Term Debt Repayments for Q4 2025 stood at -$1000.0, down from $42.6 million in the prior quarter.
- The five-year high for Long-Term Debt Repayments was $42.6 million in Q1 2025, with the low at -$1000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Mar 31, 2025 | 42.58 Mn |
| Mar 31, 2025 | 42.58 Mn |